Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

por Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P., Doshi, Sameer
Publicado 2018

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

por Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.
Publicado 2018

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

por Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Publicado 2018

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol‐Lowering Therap...

por Chan, Dick C., Watts, Gerald F., Coll, Blai, Wasserman, Scott M., Marcovina, Santica M., Barrett, P. Hugh R.
Publicado 2019

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies

por Stroes, Erik, Robinson, Jennifer G., Raal, Frederick J., Dufour, Robert, Sullivan, David, Kassahun, Helina, Ma, Yuhui, Wasserman, Scott M., Koren, Michael J.
Publicado 2018

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

por Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Publicado 2019

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

por Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Publicado 2016

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

por Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk
Publicado 2016

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV

por Nelson, Adam J., Puri, Rishi, Brennan, Danielle M., Anderson, Todd J., Cho, Leslie, Ballantyne, Christie M., Kastelein, John JP., Koenig, Wolfgang, Kassahun, Helina, Somaratne, Ransi M., Wasserman, Scott M., Nissen, Steven E., Nicholls, Stephen J.
Publicado 2020